Hikma And Reddy’s Tell Supreme Court To Throw Out Vascepa Appeal
Amarin Has Petitioned Supreme Court For Certiorari Review
Certiorari review of a Federal Circuit decision invalidating Vascepa patents “is not warranted,” Hikma and Dr Reddy’s Laboratories have argued, claiming that the premise of originator Amarin’s petition to the US Supreme Court is “false.”
You may also be interested in...
Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
US Supreme Court Gives PTO Director Chance To Impact Outcome Of Patent Disputes
High court finds PTAB judges were unconstitutionally appointed; ruling is unlikely to benefit one party over another in inter partes review proceedings, attorneys say, but that could depend on the director. PTO is expected to provide guidance on how and when to request review of Patent Trial and Appeal Board decisions.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.